IL-18: The "Igniter" of Inflammatory Storms, A Central Hub Linking Immune Defense and Chronic Diseases

Interleukin-18 (IL-18) is a key member of the IL-1 cytokine superfamily, renowned for its potent pro-inflammatory and interferon-γ-inducing capabilities. As a "pioneer signal" of immune responses, it serves as both a weapon against infections and a "culprit" driving numerous chronic inflammatory and autoimmune diseases. This article will delve into the unique activation mechanisms and biological functions of IL-18, comprehensively explore its central role in autoinflammatory diseases, autoimmune disorders, metabolic syndrome, neurodegenerative diseases, and severe infections, and展望 its clinical prospects as a diagnostic biomarker and therapeutic target.

I. IL-18: An Immune Sword Requiring "Two Keys" for Activation

IL-18 is primarily produced by innate immune cells such as macrophages and dendritic cells. Unlike most cytokines that can be directly secreted, the synthesis and release of IL-18 are tightly controlled by a dual-layer mechanism, making it a "safety switch" for initiating intense inflammatory responses.

1. Unique "Two-Step Activation" Model

Its activation process can be likened to a missile requiring two unlocks to launch:

• Step 1: Precursor Synthesis (Building the Missile): When cells detect pathogens or damage signals through pattern recognition receptors (e.g., TLRs), they activate pathways such as NF-κB to synthesize biologically inactive IL-18 precursor, which is stored in the cytoplasm.
• Step 2: Cleavage Activation (Igniting the Fuse): Upon encountering a second danger signal (e.g., ATP, uric acid crystals, or cell damage products), cells assemble a protein complex called the inflammasome. The inflammasome (particularly the NLRP3 inflammasome) activates the protease caspase-1, which cleaves the IL-18 precursor to generate fully active mature IL-18, which is then released extracellularly.

2. Potent Biological Effects

Once released, mature IL-18 binds to the IL-18 receptor on target cells, exerting broad effects:

• Induction of IFN-γ Production: Synergizing with IL-12, it strongly activates T cells and NK cells to produce γ-interferon, which is central to antiviral and intracellular antibacterial immunity.
• Driving Inflammatory Cascades: It promotes the release of other inflammatory cytokines like TNF-α and IL-1β and activates vascular endothelial cells, leading to fever, vasodilation, and leukocyte recruitment (redness, swelling, heat, and pain).

II. The Deep Connection Between IL-18 Dysregulation and Major Diseases

Precise balance of IL-18 signaling is crucial. Its excessive or uncontrolled activation is a common pathological basis for many diseases.

1. Autoinflammatory Diseases

These are diseases caused by the direct overactivation of the innate immune system, where IL-18 plays a "culprit" role.

Familial Mediterranean Fever: A genetic disorder associated with mutations in the pyrin protein gene, leading to abnormal inflammasome activation and periodic bursts of IL-18 and other cytokines, manifesting as recurrent fever and serositis.

Gout: A classic example. Urate crystals formed from supersaturated uric acid are phagocytosed by immune cells, strongly activating the NLRP3 inflammasome and causing explosive release of IL-18 and IL-1β, resulting in intense joint redness, swelling, heat, and pain.

Cryopyrin-Associated Periodic Syndromes: Caused by direct mutations in the NLRP3 gene, leading to "uncontrolled" inflammasome activity and continuous IL-18 production, resulting in systemic inflammation.

2. Autoimmune Diseases

Systemic Lupus Erythematosus: Serum IL-18 levels are significantly elevated in patients and positively correlate with disease activity. IL-18 promotes autoreactive T cells and pathogenic antibody production, exacerbating organ damage (e.g., kidneys).

Rheumatoid Arthritis: In joint synovial fluid, IL-18 drives synovial cell inflammation and osteoclast activation, leading to joint destruction.

Inflammatory Bowel Disease: In Crohn's disease and ulcerative colitis, elevated IL-18 levels in the intestinal mucosa disrupt the epithelial barrier and drive chronic intestinal inflammation.

3. Metabolic and Cardiovascular Diseases

Chronic low-grade inflammation is a common feature of these diseases, and IL-18 is a key "instigator."

Type 2 Diabetes and Obesity: Adipose tissue is not only an energy reservoir but also an active inflammatory organ. In obesity, adipose tissue continuously secretes IL-18 and other factors, inducing insulin resistance and potentially directly impairing pancreatic β-cell function.

Atherosclerosis: In arterial plaques, cholesterol crystals activate the NLRP3 inflammasome in macrophages, producing IL-18. IL-18 promotes plaque inflammation, instability, and thrombosis, playing a key role in myocardial infarction and stroke.

4. Neurodegenerative Diseases

Inflammation in the brain (neuroinflammation) is critical to disease progression.

Alzheimer's Disease: β-amyloid plaques in the brain can activate the inflammasome in microglia, releasing IL-18. Persistent neuroinflammation exacerbates neuronal damage and cognitive decline.

Parkinson's Disease: Similar mechanisms may be involved, with IL-18 amplifying neurotoxic inflammatory responses.

5. Severe Infections and Cytokine Storm

Sepsis and Severe COVID-19: In severe systemic infections, IL-18 is a core member of the "cytokine storm." Its excessive release leads to systemic inflammation, capillary leakage, and multi-organ failure, closely associated with high mortality.

III. Clinical Prospects: From Diagnostic Biomarker to Targeted Therapy

Given IL-18's central role in diseases, it has become an important diagnostic and therapeutic target.

1. As a Biomarker

• Disease Activity Assessment: Measuring serum IL-18 levels can help assess disease activity and prognosis in SLE, RA, HLH, etc.
• Differential Diagnosis: Elevated IL-18 levels in autoinflammatory diseases can serve as auxiliary diagnostic indicators.

2. As a Therapeutic Target

Multiple strategies aim to neutralize excessive IL-18 activity:

• Recombinant IL-18 Binding Protein: A natural IL-18 inhibitor in humans, acting as a "decoy" receptor to bind and neutralize free IL-18. Recombinant human IL-18BP is in clinical trials for autoinflammatory diseases.
• Anti-IL-18 Neutralizing Monoclonal Antibodies: Directly target and neutralize IL-18 molecules. Drugs like GSK1070806 and Tadekinig alfa have shown promise in clinical trials for adult-onset Still's disease and HLH.
• Upstream Inhibitors: Small-molecule inhibitors targeting the inflammasome (e.g., NLRP3) to block IL-18 production at its source are a hot area of drug development.

IV. Challenges and Future Perspectives

• Precision Modulation Challenges: How to precisely inhibit IL-18's pathological effects in specific diseases without compromising its anti-infection physiological functions is key to drug design.
• Combination Therapy: IL-18 signaling often intertwines with other inflammatory pathways, necessitating future development of combination therapies with anti-TNF, anti-IL-1, or anti-IL-6 drugs.
• Expanding Indications: The potential of anti-IL-18 therapies in neurodegenerative and metabolic diseases remains to be explored.

Conclusion

The IL-18 protein, with its sophisticated "two-step activation" mechanism and potent pro-inflammatory capabilities, sits at a critical node in the inflammatory network. Like a double-edged sword, it is a loyal defender against invaders in physiological states but becomes a "tyrant" igniting self-tissues and driving chronic diseases in pathological states. From the excruciating pain of gouty joints to the chronic inflammation behind diabetes and the silent damage in the brains of Alzheimer's patients, IL-18 is ubiquitous. Successful development of IL-18-targeting drugs not only validates its central role in diseases but also marks the dawn of a new era in precision anti-inflammatory therapy. With deeper understanding of IL-18 signaling and more precise modulation tools, we may bring breakthrough treatments to patients with inflammatory diseases.